… pneumoniae in the present study. Therefore our findings suggest that the beneficial effects
of rapamycin in the prevention of in-stent restenosis might partly be explained by its inhibition …

… Chronic Chlamydia pneumoniae infections have been associated … COX inhibitors and
rapamycin can inhibit the infectivity of C. … of allograft and in-stent restenosis may be partly due to its …

… , EB virus) and bacteria (Chlamydia pneumoniae, HP) are … (iNOS), which at least in part
contributes to the depression of … administered rapamycin inhibits in-stent neointimal growth in …

… Conventional antibiotics mostly target the multiplication phase, which may not, however, …
used for restenosis prevention in patients with coronary artery disease in the form of rapamycin-…

… pylori, and Chlamydia pneumoniae. Infectious agents … restenosis,[111] [134] and, because
rapamycin can inhibit its … in preventing infection-induced in-stent restenosis might be the use …

… may play an important role in determining in-stent restenosis … including cytomegalovirus,
Chlamydia pneumoniae, Epstein-… inhibiting the expression of such genes, rapamycin may lead …

… could partially explain the reduction of coronary in-stent … have been developed intended to
prevent in-stent restenosis. … from a pathogen such as Chlamydia pneumoniae [32] or an auto-…

… might benefit the most from therapeutic rapamycin, the elderly, are also at increased risk for
bacterial pneumonia due in part … contrast, rapamycin inhibited the development of Chlamydia …

… , we developed a stent-coating platform that can be operated … that these stents may efficiently
inhibit in-stent restenosis in … an increase in rapamycin dosage on DES may lead to a more …

… However, in-stent restenosis presents a new and an even … frequently implicated is Chlamydia
pneumoniae, a common … Rapamycin is a cytostatic drug that induces late G1 cell-cycle …